NervGen Pharma Corp.

Play Interview



Primary Exchange/Symbol


Listing By Way Of


Shares Issued, Outstanding


Investor Information

Bill Radvak is a co-founder of NervGen and has been the CEO and director of multiple startup companies. He was a founder and the CEO of Response Biomedical, a publicly listed medical device company, which he led from its inception to a 90-employee, sales and manufacturing company. 778-888-4101

Nature Of The business

NervGen is restoring life's potential by creating innovative solutions for the treatment of nerve damage. Its core technology targets protein tyrosine phosphatase sigma (PTPσ), a neural receptor that impedes nerve regeneration. Inhibition of the PTPσ receptor has been shown to promote regeneration of damaged nerves and improvement of nerve function in animal models for various medical conditions. NervGen is advancing a drug candidate into the clinic initially for the treatment of spinal cord injury while leveraging the technology to identify additional therapeutic candidates for other related medical conditions.